Ingrid Cecilia Glimelius

List of Publications by Year
in descending order

93 papers	2,499 citations	346980 22 h-index	242451 47 g-index
94 all docs	94 docs citations	94 times ranked	3247 citing authors

#	Article	IF	Citations
1	Unilateral or Bilateral Retroperitoneal Lymph Node Dissection in Nonseminoma Patients with Postchemotherapy Residual Tumour? Results from RETROP, a Population-based Mapping Study by the Swedish Norwegian Testicular Cancer Group. European Urology Oncology, 2022, 5, 235-243.	2.6	11
2	Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy. Journal of Clinical Oncology, 2022, 40, 1487-1496.	0.8	6
3	Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark. Blood Cancer Journal, 2022, 12, 16.	2.8	3
4	Checkpoint <scp>CD47</scp> expression in classical Hodgkin lymphoma. British Journal of Haematology, 2022, 197, 580-589.	1.2	12
5	Cardiovascular disease in patients with chronic lymphocytic leukemia: A Swedish nationwide register study with matched comparators. American Journal of Hematology, 2022, 97, .	2.0	2
6	Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen â€“ a real world study on patients diagnosed in Sweden 2007-2017. Haematologica, 2022, 107, 740-743.	1.7	9
7	Late relapses in Hodgkin lymphoma â€“ should we search for the needle in the haystack?. British Journal of Haematology, 2022, 198, 11-13.	1.2	2
8	Clinical characteristics and outcomes among 2347 patients aged â‰¥85Âyears with major lymphoma subtypes: a Nordic Lymphoma Group study. British Journal of Haematology, 2021, 192, 551-559.	1.2	6
9	Maternal health, in-utero, and perinatal exposures and risk of thyroid cancer in offspring: a Nordic population-based nested case-control study. Lancet Diabetes and Endocrinology,the, 2021, 9, 94-105.	5.5	10
10	Infiltration of CD163â€, PDâ€L1â€•and FoxP3â€positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors. British Journal of Haematology, 2021, 193, 520-531.	1.2	12
11	Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma. Haematologica, 2021, 106, 2502-2506.	1.7	8
12	Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma. Blood Advances, 2021, 5, 1671-1681.	2.5	13
13	Unmarried or less-educated patients with mantle cell lymphoma are less likely to undergo a transplant, leading to lower survival. Blood Advances, 2021, 5, 1638-1647.	2.5	8
14	Cancer Risk in Individuals With Major Birth Defects: Large Nordic Population Based Case-Control Study Among Children, Adolescents, and Adults. Obstetrical and Gynecological Survey, 2021, 76, 191-193.	0.2	0
15	Realâ€world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000â€“2014, focusing on patients agedÂ>60 years. EJHaem, 2021, 2, 400-412.	0.4	3
16	Age is the most important predictor of survival in diffuse large Bâ€cell lymphoma patients achieving eventâ€free survival at 24 months: a Swedish populationâ€based study. British Journal of Haematology, 2021, 193, 906-914.	1.2	12
17	Parenthood Rates and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors: A Danish Population-Based Study. Journal of Clinical Oncology, 2021, 39, 3463-3472.	0.8	10
18	Clinical characteristics and factors associated with COVID-19-related death and morbidity among hospitalized patients with cancer: a Swedish cohort study. Acta OncolÃ³gica, 2021, 60, 1459-1465.	0.8	3

#	Article	IF	Citations
19	Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3. HemaSphere, 2021, 5, e510.	1.2	18
20	Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes. International Journal of Cancer, 2021, , .	2.3	1
21	Late Effects after Treatment in Mantle Cell Lymphoma: No Difference By Intensity of First-Line Regimens with or without Autologous Stem Cell Transplantation. Blood, 2021, 138, 1344-1344.	0.6	0
22	Associations of pregnancyâ€related factors and birth characteristics with risk of endometrial cancer: A Nordic populationâ€based caseâ€“control study. International Journal of Cancer, 2020, 146, 1523-1531.	2.3	12
23	Surgical Complications in Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumour: A Population-based Study from the Swedish Norwegian Testicular Cancer Group. European Urology Oncology, 2020, 3, 382-389.	2.6	28
24	No excess longâ€term mortality in stage Iâ€IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. British Journal of Haematology, 2020, 188, 685-691.	1.2	16
25	Comorbidities and sex differences in causes of death among mantle cell lymphoma patients â€“ A nationwide populationâ€based cohort study. British Journal of Haematology, 2020, 189, 106-116.	1.2	13
26	Increasing prevalence of chronic lymphocytic leukemia with an estimated future rise: A nationwide populationâ€based study. American Journal of Hematology, 2020, 95, E36-E38.	2.0	6
27	Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma. Immunobiology, 2020, 225, 151872.	0.8	1
28	High prevalence and incidence of cardiovascular disease in chronic lymphocytic leukaemia: a nationwide populationâ€based study. British Journal of Haematology, 2020, 190, e245-e248.	1.2	14
29	Cancer risk in individuals with major birth defects: large Nordic population based case-control study among children, adolescents, and adults. BMJ, The, 2020, 371, m4060.	3.0	23
30	p53 is associated with highâ€risk and pinpointsTP53missense mutations in mantle cell lymphoma. British Journal of Haematology, 2020, 191, 796-805.	1.2	31
31	Marginal zone lymphoma expression of histidineâ€rich glycoprotein correlates with improved survival. EJHaem, 2020, 1, 199-207.	0.4	1
32	Birthweight and all-cause mortality after childhood and adolescent leukemia: a cohort of children with leukemia from Denmark, Norway, Sweden, and Washington State. Acta OncolÃ³gica, 2020, 59, 949-958.	0.8	2
33	Trends in the prevalence, incidence and survival of nonâ€Hodgkin lymphoma subtypes during the 21st century â€“ a Swedish lymphoma register study. British Journal of Haematology, 2020, 189, 1083-1092.	1.2	24
34	Pregnancy-related risk factors for sex cord-stromal tumours and germ cell tumours in parous women: a registry-based study. British Journal of Cancer, 2020, 123, 161-166.	2.9	3
35	Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible. Blood, 2020, 136, 15-15.	0.6	7
36	Nationwide Investigation of Patient Trajectories in Mantle Cell Lymphoma - Initial Data from the Swedish MCL Complete Project. Blood, 2020, 136, 3-4.	0.6	0

#	Article	IF	Citations
37	Distribution of hospital care among pediatric and young adult Hodgkin lymphoma survivorsâ€"A populationâ€based cohort study from Sweden and Denmark. Cancer Medicine, 2019, 8, 4918-4927.	1.3	3
38	EARLY PROGRESSION OF MANTLE CELL LYMPHOMA DEPICTS A HIGH-RISK DISEASE WITH POOR RESPONSE TO SUBSEQUENT THERAPIES AND A DISMAL OUTCOME. Hematological Oncology, 2019, 37, 242-242.	0.8	0
39	Temporal trends in treatmentâ€related incidence of diseases of the circulatory system among Hodgkin lymphoma patients. International Journal of Cancer, 2019, 145, 1200-1208.	2.3	3
40	Cancer therapy and risk of congenital malformations in children fathered by men treated for testicular germ-cell cancer: A nationwide register study. PLoS Medicine, 2019, 16, e1002816.	3.9	17
41	Socioeconomic impact of Hodgkin lymphoma in adult patients: a systematic literature review. Leukemia and Lymphoma, 2019, 60, 3116-3131.	0.6	13
42	Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study. Journal of Clinical Oncology, 2019, 37, 703-713.	0.8	22
43	Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large Bâ€cell lymphoma: a Swedish lymphoma register study. Journal of Internal Medicine, 2019, 285, 455-468.	2.7	27
44	High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of Bâ€symptoms. British Journal of Haematology, 2019, 184, 192-201.	1.2	19
45	PF379ÂPREVALENCE AND INCIDENCE OF CARDIOVASCULAR DISEASE IN CHRONIC LYMPHOCYTIC LEUKEMIA: A NATIONâ€WIDE POPULATIONâ€BASED STUDY. HemaSphere, 2019, 3, 141-142.	1.2	2
46	Autologous Stem Cell Transplantation in Mantle Cell Lymphoma - Selection Mechanisms and Survival By Age Group. Blood, 2019, 134, 4572-4572.	0.6	0
47	Fertility Rates in Young Hodgkin Lymphoma Survivors: A Danish Nationwide Cohort Study of 769 Patients. Blood, 2019, 134, 2841-2841.	0.6	0
48	The role of pregnancy, perinatal factors and hormones in maternal cancer risk: a review of the evidence. Journal of Internal Medicine, 2018, 283, 430-445.	2.7	88
49	Short- and long-term risks of cardiovascular disease following radiotherapy in rectal cancer in four randomized controlled trials and a population-based register. Radiotherapy and Oncology, 2018, 126, 424-430.	0.3	10
50	An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome. European Journal of Haematology, 2018, 100, 88-97.	1.1	22
51	Hodgkin lymphoma in children, adolescents and young adults â€“ a comparative study of clinical presentation and treatment outcome. Acta OncolÃ³gica, 2018, 57, 276-282.	0.8	12
52	Contemporarily Treated Patients With Hodgkin Lymphoma Have Childbearing Potential in Line With Matched Comparators. Journal of Clinical Oncology, 2018, 36, 2718-2725.	0.8	13
53	Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma. PLoS ONE, 2018, 13, e0204870.	1.1	26
54	Preterm delivery is associated with an increased risk of epithelial ovarian cancer among parous women. International Journal of Cancer, 2018, 143, 1858-1867.	2.3	11

#	Article	IF	Citations
55	Pregnancy complications and subsequent breast cancer risk in the mother: a <scp>N</scp>ordic populationâ€based caseâ€“control study. International Journal of Cancer, 2018, 143, 1904-1913.	2.3	13
56	Greater attention should be paid to developing therapies for elderly patients with Hodgkin lymphomaâ€”A populationâ€based study from Sweden. European Journal of Haematology, 2018, 101, 106-114.	1.1	23
57	Relapse Risk and Loss in Expectation of Lifetime in Young Classical Hodgkin Lymphoma Patients - a Nordic Lymphoma Group Study of 2,582 Patients. Blood, 2018, 132, 930-930.	0.6	1
58	Prognostic Implications of Specific Comorbidities in Mantle Cell Lymphoma Patients, a Swedish Lymphoma Registry Study. Blood, 2018, 132, 2891-2891.	0.6	0
59	Continuous Increasing Prevalence of Chronic Lymphocytic Leukemia (CLL) with an Estimated Future Riseâ€”a Nationwide Population-Based Study from Sweden. Blood, 2018, 132, 3120-3120.	0.6	0
60	Increased healthcare use up to 10 years among relapseâ€free Hodgkin lymphoma survivors in the era of intensified chemotherapy and limited radiotherapy. American Journal of Hematology, 2017, 92, 251-258.	2.0	13
61	Possible Interaction Between Cigarette Smoking and HLA-DRB1 Variation in the Risk of Follicular Lymphoma. American Journal of Epidemiology, 2017, 185, 681-687.	1.6	10
62	Novel treatment concepts in Hodgkin lymphoma. Journal of Internal Medicine, 2017, 281, 247-260.	2.7	32
63	UNMET MEDICAL NEEDS IN HODGKIN LYMPHOMA WITH SPECIAL FOCUS ON THE ELDERLY â€“ a POPULATIONâ€BASED STUDY OF PATIENTS DIAGNOSED IN SWEDEN 1973â€2014. Hematological Oncology, 2017, 35, 100-101.	0.8	0
64	MORTALITY RATES REMAIN INCREASED IN YOUNG PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA EVEN AFTER YEARS IN REMISSION: RESULTS FROM A NORDIC LYMPHOMA GROUP STUDY. Hematological Oncology, 2017, 35, 172-173.	0.8	0
65	Parental Age and Risk of Lymphoid Neoplasms. American Journal of Epidemiology, 2017, 186, 1159-1167.	1.6	4
66	High proportions of PD-1+ and PD-L1+ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome. Blood Advances, 2017, 1, 1427-1439.	2.5	37
67	The ABC-study: A randomized phase III study comparing one course of adjuvant bleomycin, etoposide, and cisplatin (BEP) and one course of carboplatin AUC7 in clinical stage I seminomatous testicular cancer.. Journal of Clinical Oncology, 2017, 35, TPS4593-TPS4593.	0.8	2
68	Work Loss Duration and Predictors Following Rectal Cancer Treatment among Patients with and without Prediagnostic Work Loss. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 987-994.	1.1	12
69	Association between HLA-A1 and -A2 types and Epsteinâ€“Barr virus status of post-transplant lymphoproliferative disorder. Leukemia and Lymphoma, 2016, 57, 2351-2358.	0.6	15
70	The role of tumourâ€infiltrating eosinophils, mast cells and macrophages in Classical and Nodular Lymphocyte Predominant Hodgkin Lymphoma in children. European Journal of Haematology, 2016, 97, 430-438.	1.1	23
71	Reproductive history and risk of colorectal adenocarcinoma in parous women: a Nordic population-based caseâ€“control study. British Journal of Cancer, 2016, 115, 1416-1420.	2.9	5
72	Lost workdays in uterine cervical cancer survivors compared to the general population: impact of treatment and relapse. Journal of Cancer Survivorship, 2016, 10, 514-523.	1.5	8

#	Article	IF	Citations
73	Risk of lymphoid neoplasms in a Swedish population-based cohort of 337,437 patients undergoing appendectomy. Scandinavian Journal of Gastroenterology, 2016, 51, 583-589.	0.6	7
74	Pregnancy and the Risk of Relapse in Patients Diagnosed With Hodgkin Lymphoma. Journal of Clinical Oncology, 2016, 34, 337-344.	0.8	26
75	Risk of disability pension in patients following rectal cancer treatment and surgery. British Journal of Surgery, 2015, 102, 1426-1432.	0.1	18
76	The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma â€“ a Swedish population-based study. BMC Cancer, 2015, 15, 850.	1.1	60
77	Longâ€term survival in young and middleâ€aged <scp>H</scp>odgkin lymphoma patients in <scp>S</scp>weden 1992â€“2009â€”trends in cure proportions by clinical characteristics. American Journal of Hematology, 2015, 90, 1128-1134.	2.0	36
78	A Novel Risk Locus at 6p21.3 for Epsteinâ€“Barr Virus-Positive Hodgkin Lymphoma. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1838-1843.	1.1	20
79	Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up timeâ€”a population-based comparative study. Journal of Cancer Survivorship, 2015, 9, 599-609.	1.5	35
80	Sick leave and disability pension among Swedish testicular cancer survivors according to clinical stage and treatment. Acta OncolÃ³gica, 2015, 54, 1770-1780.	0.8	17
81	Autoimmune and Atopic Disorders and Risk of Classical Hodgkin Lymphoma. American Journal of Epidemiology, 2015, 182, 624-632.	1.6	25
82	Exposure to UV radiation and risk of Hodgkin lymphoma: a pooled analysis. Blood, 2013, 122, 3492-3499.	0.6	30
83	Tissue microarray and digital image analysis: a methodological study with special reference to the microenvironment in Hodgkin lymphoma. Histopathology, 2012, 61, 26-32.	1.6	8
84	Predictors of histology, tissue eosinophilia and mast cell infiltration in Hodgkinâ€™s Lymphoma - a population-based study. European Journal of Haematology, 2011, 87, 208-216.	1.1	23
85	Effect of eosinophil cationic protein (ECP) on Hodgkin lymphoma cell lines. Experimental Hematology, 2011, 39, 850-858.	0.2	17
86	The Potential Role of Innate Immunity in the Pathogenesis of Hodgkin's Lymphoma. Hematology/Oncology Clinics of North America, 2007, 21, 805-823.	0.9	27
87	Expression of Mast Cell Tryptases in Hodgkin and Reed-Sternberg (HRS) Cells. Scandinavian Journal of Immunology, 2007, 67, 071117034935002-???.	1.3	0
88	IL-9 expression contributes to the cellular composition in Hodgkin lymphoma. European Journal of Haematology, 2006, 76, 278-283.	1.1	35
89	Angiogenesis and mast cells in Hodgkin lymphoma. Leukemia, 2005, 19, 2360-2362.	3.3	40
90	Bulky disease is the most important prognostic factor in Hodgkin lymphoma stage IIB. European Journal of Haematology, 2003, 71, 327-333.	1.1	25

#	Article	IF	Citations
91	Breast Cancer Following Radiotherapy and Chemotherapy Among Young Women With Hodgkin Disease. JAMA - Journal of the American Medical Association, 2003, 290, 465.	3.8	569
92	Lung Cancer Following Chemotherapy and Radiotherapy for Hodgkin's Disease. Journal of the National Cancer Institute, 2002, 94, 182-192.	3.0	503
93	Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. British Journal of Haematology, 2002, 119, 122-124.	1.2	160